What the changes say
- Common stock and warrants were delisted from Nasdaq and later moved from OTCQB to OTCQX.
- Vedco and Clipper now generated 74% of Spryng® revenue, up from 43%; MWI and Covetrus generated zero.
- Cash fell to $201,000, with only a potential $1.5 million investment extending operations by three months.
What changed since the prior 10-K
New
- NewRisks Relating to Our Financial Condition
The Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market has resulted in a delisting of its securities
Nasdaq delisted the common stock and warrants; securities now trade on OTCQX after moving through OTCQB.
Reworded
- 43% rewrittenRisks Relating to Our Business and Industry
Our Distribution relationships with Vedco and Clipper Distributing are important to our business and if we were to lose our Distribution relationships it would adversely affect our revenues and profitability
Revenue concentration shifted to Vedco and Clipper, which accounted for 74% of Spryng® revenue versus 43%; MWI and Covetrus fell to zero.
Was: Our Distribution Agreements with Vedco and Clipper Distributing are important to our business and if we were to lose our Distribution Agreements it would adversely affect our revenues and profitability
- 36% rewrittenRisks Relating to Our Financial Condition
If we are unable to obtain sufficient funding, we may have to reduce materially or even discontinue our business
Cash declined to $201,000, and the prior expected $4.4 million financing was replaced by an optional investment of up to $1.5 million.
- 28% rewrittenRisks Relating to Our Business and Industry
If our current sales and marketing program is insufficient or inadequate to support the current introduction of our Spryng ® product, we may not be able to sell this product in quantities to become commercially successful
The sales strategy now depends on Vedco and Clipper instead of MWI and Covetrus for distribution and sales support.
All 26 risk factors
Headings as the filing states them, in filing order.
Risks Relating to Our Financial Condition
- 01The Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market has resulted in a delisting of its securitiesNew
- 02We have incurred substantial losses to date and could continue to incur such losses
- 03If we are unable to obtain sufficient funding, we may have to reduce materially or even discontinue our business36% rewritten
Risks Relating to Our Business and Industry
- 04We have a limited operating history upon which to base an evaluation of our business prospects
- 05We are substantially dependent upon the success of Spryng® and any failure of Spryng® to achieve market acceptance would harm us significantly
- 06Our lead product, Spryng ® , will face significant competition in our industry, and our failure to compete effectively may prevent us from achieving any significant market penetration
- 07We will rely on third parties to conduct studies of our current and new products, and if these third parties do not successfully perform their contracted commitments effectively or substantially fail to meet expected study deadlines, we could be delayed from effectively commercializing our future products
- 08Our operations rely on third parties to produce our raw materials to produce our products
- 09If we experience the rapid commercial growth of Spryng ® , we may not be able to manage such growth effectively
- 10Our Distribution relationships with Vedco and Clipper Distributing are important to our business and if we were to lose our Distribution relationships it would adversely affect our revenues and profitability43% rewritten
- 11If our current sales and marketing program is insufficient or inadequate to support the current introduction of our Spryng ® product, we may not be able to sell this product in quantities to become commercially successful28% rewritten
- 12Our business will depend significantly on the sufficiency and effectiveness of our marketing and product promotional programs and incentives
- 13Any damage to our reputation or our brand may materially harm our business
- 14If we fail to attract and retain qualified management and key scientific personnel, we may be unable to successfully commercialize our current products or develop new products effectively
- 15Natural disasters and other events beyond our control could materially adversely affect us
Risks relating to Manufacturing
- 16We may not be able to manage our manufacturing and supply chain effectively, which would harm our results of operations
Risks relating to our Intellectual Property
- 17Failure to protect our intellectual property could harm our competitive position or cause us to incur significant expenses and personnel resources to enforce our rights
- 18We may be subject to intellectual property infringement claims, which could result in substantial damages and diversion of the efforts and attention of our management
Risks related to Regulation
- 19We may be unable to obtain required regulatory approvals for future products timely or at all, and the denial or substantial delay of any such approval could delay materially or even prevent our efforts to commercialize new products, which could adversely impact our ability to generate future revenues
Risks relating to our Information Technology
- 20A failure of one or more key information technology systems, networks, or processes may harm our ability to conduct our business effectively
Risks Related to our Company
- 21Ownership and control of our Company is concentrated in our management
- 22The market price of our common stock has been volatile in the past and the market price of our common stock and our warrants is likely to be highly volatile in the future. You may not be able to resell shares of our common stock following periods of volatility because of the market’s adverse reaction to volatility
- 23Our common stock has in the past been a “penny stock” under SEC rules, and if our common stock is deemed to be a “penny stock,” it will be more difficult to resell our securities
- 24We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”) and if we fail to continue to comply, our business could be harmed, and the price of our securities could decline
- 25The elimination of monetary liability against our directors and executive officers under Nevada law and the existence of indemnification rights held by them granted by our bylaws could result in substantial expenditures by us
- 26Our Articles of Incorporation, Bylaws, and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline
Other PetVivo Holdings 10-Ks
- FY2025 10-K risk factors25 risks
PetVivo faces severe liquidity risk with only one month of cash remaining as of March 31, 2025. The business is heavily dependent on the commercial success and distribution of its single lead product, Spryng. Operations rely entirely on third-party raw material suppliers and clinical study partners.
Filed Jul 10, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.